US8465413B2 - Method of treating Peyronie's disease - Google Patents

Method of treating Peyronie's disease Download PDF

Info

Publication number
US8465413B2
US8465413B2 US12/954,633 US95463310A US8465413B2 US 8465413 B2 US8465413 B2 US 8465413B2 US 95463310 A US95463310 A US 95463310A US 8465413 B2 US8465413 B2 US 8465413B2
Authority
US
United States
Prior art keywords
penis
length
erect
peyronie
affected
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active, expires
Application number
US12/954,633
Other versions
US20120136206A1 (en
Inventor
Sarah J. Deitch
Janell Colley
Julie M. Kerkvliet
Gregg Ledin
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Coloplast AS
Original Assignee
Coloplast AS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Coloplast AS filed Critical Coloplast AS
Priority to US12/954,633 priority Critical patent/US8465413B2/en
Assigned to COLOPLAST A/S reassignment COLOPLAST A/S ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: KERKVLIET, JULIE, MS., LEDIN, GREGG, MR., COLLEY, JANELL, MS., DEITCH, SARAH J., MS.
Priority to US13/189,580 priority patent/US8206282B2/en
Priority to EP11794630.1A priority patent/EP2642949B1/en
Priority to PCT/DK2011/050448 priority patent/WO2012069060A1/en
Priority to ES11794630.1T priority patent/ES2560629T3/en
Publication of US20120136206A1 publication Critical patent/US20120136206A1/en
Application granted granted Critical
Publication of US8465413B2 publication Critical patent/US8465413B2/en
Active legal-status Critical Current
Adjusted expiration legal-status Critical

Links

Images

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61FFILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F5/00Orthopaedic methods or devices for non-surgical treatment of bones or joints; Nursing devices; Anti-rape devices
    • A61F5/41Devices for promoting penis erection
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61FFILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F5/00Orthopaedic methods or devices for non-surgical treatment of bones or joints; Nursing devices; Anti-rape devices
    • A61F5/41Devices for promoting penis erection
    • A61F2005/411Penile supports

Landscapes

  • Health & Medical Sciences (AREA)
  • Reproductive Health (AREA)
  • Nursing (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Vascular Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Orthopedics, Nursing, And Contraception (AREA)

Abstract

A method of treating Peyronie's disease manifested in an erect penis having a first penis side with an unaffected length and a second penis side with an affected length that is shorter than the unaffected length includes attaching an elastic device subcutaneously to the first penis side; and providing the elastic device with a stretch stop that limits elongation of the first penis side to an erection distance that is approximately equal to the affected length of the erect penis.

Description

BACKGROUND
Peyronie's disease is manifested by an abnormal bend that occurs in the erect penis of the sufferer and can be associated with painful erection and/or painful intercourse.
Peyronie's disease is related to the development of scar tissue, or plaques, that form on tissues (e.g., tunica albuginea) inside the penis. One non-surgical approach for the treatment of Peyronie's disease includes injecting drugs into the plaques that lessen the compression applied by the plaques to the erect penis. The research and efficacy of this approach is limited.
Surgical treatments for Peyronie's disease include excising portions of the tunica albuginea from the penis opposite the plaque and closing the fenestrations with sutures. Access to the tunica albuginea is achieved by first degloving the penile skin away from the penis to expose the Buck's fascia and tunica albuginea along the length of the penis. Degloving the penile skin is painful and the recovery time for the patient can be several weeks. Although the long term results of this surgical approach are good, both short term (within 8 weeks) and long term failures can present with residual penile deformity.
Another surgical treatment includes corporal plication in which plication sutures are placed on the contralateral side of the plaque without excising the tunica albuginea or removing the plaque. Corporal plication is most commonly employed subsequent to a previous Peyronie's treatment surgery to correct small angles of residual penile deformity.
Patients and clinicians desire more effective and less invasive surgical treatments for Peyronie's disease.
SUMMARY
One aspect provides a Peyronie's treatment device configured to treat an erect penis having curvature characterized by a first penis side with an unaffected length and a second penis side with an affected length that is shorter than the unaffected length. The device includes a band connected between a proximal support that is attachable to a base of a penis and a distal support that is attachable adjacent a corona of the penis. The band has an elastic material and a second material that is attached to the elastic material. The second material is provided to stop elongation of the elastic material at a length approximately equal to the affected length of the erect penis.
One aspect provides a method of treating Peyronie's disease manifested in an erect penis having a first penis side with an unaffected length and a second penis side with an affected length that is shorter than the unaffected length. The method includes attaching an elastic device subcutaneously to the first penis side; and providing the elastic device with a stretch stop that limits elongation of the first penis side to an erection distance that is approximately equal to the affected length of the erect penis.
BRIEF DESCRIPTION OF THE DRAWINGS
The accompanying drawings are included to provide a further understanding of embodiments and are incorporated in and constitute a part of this specification. The drawings illustrate embodiments and together with the description serve to explain principles of embodiments. Other embodiments and many of the intended advantages of embodiments will be readily appreciated as they become better understood by reference to the following detailed description. The elements of the drawings are not necessarily to scale relative to each other. Like reference numerals designate corresponding similar parts.
FIG. 1A is a top view and FIG. 1B is a cross-sectional view of one embodiment of a Peyronie's treatment device having an elastic material in a relaxed state.
FIG. 2A is a top view and FIG. 2B is a cross-sectional view of one embodiment of the Peyronie's treatment device illustrated in FIGS. 1A and 1B with the elastic material stopped in a stretched state by a second material that is attached to the elastic material.
FIG. 3A is a side schematic view of an erect penis afflicted by Peyronie's disease.
FIG. 3B is a side schematic view of the penis illustrated in FIG. 3A in a flaccid state and including the treatment device illustrated in FIGS. 1A and 1B attached to the tunica albuginea of the penis.
FIG. 3C is a side schematic of the penis illustrated in FIG. 3B in an erect state having reduced curvature as compared to the untreated penis illustrated in FIG. 3A.
FIG. 4A is a top view of one embodiment of a Peyronie's treatment device in a relaxed, un-stretched state.
FIG. 4B is a top view of a band of the device illustrated in FIG. 4A showing a stop strand.
FIG. 4C is a top view of the Peyronie's treatment device illustrated in FIG. 4A in an elongated state.
FIG. 4D is a top view of the band of the device illustrated FIGS. 4A and 4C showing the stop strand limiting elongation of the device.
FIG. 5 is a perspective view of one embodiment of a Peyronie's treatment device.
FIG. 6 is a block diagram of one embodiment of a method of treating Peyronie's disease.
FIG. 7 is a block diagram of one embodiment of a method of treating Peyronie's disease.
DETAILED DESCRIPTION
In the following Detailed Description, reference is made to the accompanying drawings, which form a part hereof, and in which is shown by way of illustration specific embodiments in which the invention may be practiced. In this regard, directional terminology, such as “top,” “bottom,” “front,” “back,” “leading,” “trailing,” etc., is used with reference to the orientation of the Figure(s) being described. Because components of embodiments can be positioned in a number of different orientations, the directional terminology is used for purposes of illustration and is in no way limiting. It is to be understood that other embodiments may be utilized and structural or logical changes may be made without departing from the scope of the present invention. The following detailed description, therefore, is not to be taken in a limiting sense, and the scope of the present invention is defined by the appended claims.
It is to be understood that the features of the various exemplary embodiments described herein may be combined with each other, unless specifically noted otherwise.
Soft tissue includes dermal tissue, sub-dermal tissue, ligaments, tendons, or membranes but does not include bone.
The term “proximal” as employed in this application means that part that is situated next to or near the point of attachment or origin or a central point: as located toward a center of the human body. The term “distal” as employed in this application means that part that is situated away from the point of attachment or origin or the central point: as located away from the center of the human body. A distal end is the furthest endmost location of a distal portion of a thing being described, whereas a proximal end is the nearest endmost location of a proximal portion of the thing being described. For example, the glans penis is located distal and of the crus of the penis is located proximal relative to the male body such that a distal end of a corpora cavernosum of the patient extends about midway into the glans penis.
Embodiments provide an internal traction device that treats the effects of Peyronie's disease by reducing the curvature of an erect penis. In one embodiment, the device is attached subcutaneously to an exterior surface of the tunica albuginea on a contralateral side of the penis opposite the side on which the Peyronie's plaques have formed and functions to counteract the asymmetrical contraction of the penis caused by the Peyronie's plaques. The device is fabricated from a stretchy material that accommodates movement of the penis between a flaccid state and an erect state. The device is configured to stretch and elongate up to a built-in stop-limit that is selected to match the length of the penis on the side on which the Peyronie's plaques have formed. In this manner, all sides of the penis elongate to an approximately equal length.
In one embodiment, the device is attached to the tunica albuginea of the penis without incising the tunica or removing the Peyronie's plaques, and thus use of the device limits patient discomfort and reduces the healing time for the Peyronie's-afflicted patient compared to other procedures.
FIG. 1A is a top view and FIG. 1B is a cross-sectional view of one embodiment of a Peyronie's treatment device 20. The Peyronie's treatment device 20 (device 20) is provided as a band 20 that includes an elastic material 22 extending between a proximal support 24 that is attachable to a base of a penis and distal support 26 that is attachable adjacent a corona of the penis, and includes a second material 28 attached to the elastic material 22. In one embodiment, the device 20 provides attachment locations 30 that allow the device 20 to be attached subcutaneously within the penis.
Patients who suffer from Peyronie's disease develop a curvature in the erect penis characterized by one side of the penis having an unaffected length and, generally, an opposite side of the penis having an affected length that is shorter than the unaffected length of the penis. The band 20 provides a length that is selected to stretch between a first initial length L1 extending between a base of the penis and a corona of the penis when the penis is flaccid to a final length L2 (FIG. 2) that is approximately equal to be affected length of the penis. The elastic material 22 is thus configured to move with the penis between its flaccid state and its erect state, and when the penis is erect, the device 20 is configured to straighten the penis to an approximately symmetric shape/length.
In one embodiment, the second material 28 provides a stop for the elastic material 22 that allows the elastic material 22 to stretch from the initial length L1 to the final length L2, where the final length L2 is selected prior to surgery to be approximately equal to the affected length of the Peyronie's-affected erect penis. In one embodiment, the second material 28 provides means for limiting elongation of the stretchable band 20 to a distance that is greater than the affected length of the Peyronie's-affected erect penis.
In one embodiment, the band 20 is elastically deformable between the initial length L1 and the final length L2 and the second material 28 configures the band 20 to be inelastically deformable past the final length L2. That is to say, the band 20 is stretchable up to the final length L2, and if a sufficiently large force is applied to the band 20 to stretch it beyond the length L2, the band will fracture or otherwise break. Thus, the elastic material 22 is stretchable from the initial length L1 that is less than the affected length to a length that is greater than the affected length, and the second material 28 prevents elongation of the elastic material 22 past the affected length.
In one embodiment, the elastic material 22 is provided as a knitted fabric and the second material 28 is provided as a separate fabric 28 that is attached to the knitted fabric 22, where the separate fabric 28 has some limited degree of stretch that allows the elastic material 22 to stretch up to the desired the final length L2 before the separate fabric 28 stops the elongation of the elastic material 22 at the final length L2. The separate fabric 28 thus allows the elastic material 22 to stretch up to but not beyond the final length L2. With this in mind, one embodiment of the band 20 includes stretching the elastic material 22 to the final length L2 and attaching the separate fabric 28 to the elastic material 22. When the elastic material 22 is relaxed the separate fabric 28 moves with the elastic material 22. When the elastic material 22 is stretched, the separate fabric 28 moves to allow the elastic material 22 to stretch up to but not beyond the final length L2.
In one embodiment, the elastic fabric 22 is provided as a knitted fabric and the second material 28 is provided as an inelastic woven fabric that is attached to the knitted fabric. In one embodiment, the inelastic woven fabric 28 has a fixed length generally equal to L2 and is attached to the elastic fabric 22 in a manner (similar to that described above) that allows the elastic material 22 to stretch up to but not beyond the final length L2.
In one embodiment, the elastic material 22 is provided as a knitted fabric and the second material 28 is provided as inelastic strand 28 embedded in the knitted fabric. As an example, the elastic material 22 is stretched to the final length L2 and the inelastic strand 28 is attached to the elastic material 22 to limit its elongation. In one embodiment, the inelastic strand 28 is fixed to the elastic fabric 22 in a manner that allows the elastic material 22 to stretch up to but not beyond the final length L2.
The elastic material 22 is stretchable between the initial length L1 and a length that is longer than the final length L2, and a second material 28 is provided to stop the elongation of the elastic material 22 at the final length L2. The knitted fabrics of the elastic material 22 are suitably fabricated from polymer fiber such as polypropylene, polyethylene, or polyolefin or such fibers coated with slip agents or elastic additives. The second material 28 is suitably fabricated from, as an example, nylon thread(s) woven or otherwise processed to provide a stop to the elongation of the elastic material 22 at the final length L2. The second material 28 is suitably fabricated from an inelastic suture filament.
Knitted fabrics are generally fabricated from a filament that is knit on a path to form a chain of loops, where each loop in the chain of loops is suspended by a neighboring loop. The loops are secured as they are knit by passing a newly formed loop through a previously formed loop. The chain of loops that run in a lateral direction are referred to as a wale, and the path that the knitting filament follows is referred to as a course (see FIG. 4B as an example of a knitted fabric).
A woven material is different from a knitted material in that woven material is formed by threads that run parallel in a lengthwise direction (warp threads) and cross with a separate set of parallel threads placed in a crosswise direction (weft threads). Woven materials can thus be fabricated that have little or no stretch as the warp and weft threads connect together to limit their mutual movement. In contrast, the meandering course that forms the loops of a knitted material provide the knit with greater elasticity (e.g., stretchiness) over the woven material since the loops move within each other.
With the above mind, the device 20 or the band 20 is provided in multiple formats (for example, each with a different final length L2) that allow the surgeon to select the desired final length L2 as based on the affected length of the erect penis of the patient suffering from Peyronie's disease.
FIG. 2A is a top view and FIG. 2B is a cross-sectional view of the Peyronie's treatment device 20 illustrated in FIG. 1 with the elastic material 22 stopped at a desired elongated length by the second material 28.
FIGS. 3A, 3B, and 3C are schematic views of a penis P.
FIG. 3A is a side schematic view of a Peyronie's afflicted erect penis. The erect penis P has a pair of corpora cavernosa CC that extend from a proximal location internal to the body up to a mid-location of the glans penis. The illustrated erect penis P includes plaques that have formed on an affected side 40 of the penis P that cause the erect penis P to have an affected length La. The penis P has an unaffected side 42 that is generally opposite the affected side 40 of the penis. The unaffected side 42 of the penis P has an unaffected length of Lu. The affected side 40 of the erect penis is generally shorter than the unaffected side 42 of the erect penis such that the erect penis P presents with an undesirable curvature.
FIG. 3B is a side schematic view of the penis P including the band 20 subcutaneously attached to the tunica albuginea TA of the penis P. The tunica albuginea TA of the penis P encapsulates the corpora cavernosa CC. The proximal support 24 of the band 20 is attached to a base B of the penis P and the distal support 26 is attached adjacent to a corona C of the penis P, for example by suturing through the attachment locations 30.
In one embodiment, the band 20 is attached subcutaneously to the tunica albuginea TA of a flaccid penis P. For example, the band 20 is provided in a variety of lengths that allows the surgeon to selective a band 20 having the appropriate initial length L1 and an appropriate final length L2 based on pre-treatment measurements, and knowing these lengths, the surgeon selects the appropriately sized band 20 for attachment to the flaccid penis P.
Alternatively, in one embodiment the band 20 is attached subcutaneously to the tunica albuginea TA of an erect penis P. For example, the surgeon artificially induces an erection in the penis P to observe the angle and extent of the curvature in the Peyronie's affected penis, and after recording this data, selects a band 20 having a final elongated length L2 that is approximately equal to the affected length La of the erect penis. The selected band 20 is attached to the erect penis to provide a suitable amount of correction to the curvature of the Peyronie's affected penis P.
FIG. 3C is a side schematic view of the erect penis P including plaques present on the affected side 40 of the Peyronie's afflicted penis and the band 20 attached subcutaneously to the tunica albuginea to provide a correcting force that resists curvature of the penis P. The erect penis P is thus provided with symmetric sides 40, 42 in which the band 20 configures the unaffected side 42 of the penis P to have a length that is approximately equal to the affected length La of the penis P. As illustrated by FIG. 3C, the final length L2 of the band 20 has a length that is substantially equal to the affected length La of the penis (FIG. 3A).
FIG. 4A is a top view of one embodiment of a Peyronie's treatment device 50 (device 50). The device 50 is provided with multiple bands 51 having elastic material 52 extending between a proximal support 54 that is attachable to a base of a penis and a distal support 56 that is attachable adjacent a corona of the penis, and a second material 58 attached to the elastic material 52 that is provided to stop elongation of the elastic material 52 at a length approximately equal to the affected length of a Peyronie's affected erect penis.
In one embodiment, the proximal support 54 is provided as a segment that is attachable to less than an entire circumference of the base of the penis P. In one embodiment, the distal support 56 is provided as a segment that is attachable to less than an entire circumference of the penis adjacent the corona.
FIG. 4A illustrates the device 50 having an initial length L1 in a relaxed state and FIG. 4C illustrates the device 50 stretched or elongated to a final length L2 that is selected to be substantially equal to the affected length of an erect Peyronie's affected penis.
FIG. 4B is a top view of one of the bands 51 including a filament 53 knit on a path to form a chain of loops 55, where each loop 57 in the chain of loops 55 is suspended by a neighboring loop 59. In this manner, the loops 55 are secured as they are knit by passing a newly formed loop (e.g., loop 57) through a previously formed loop (e.g., loop 59). The chain of loops that run left-to-right in FIG. 4B are referred to as a wale W. The path that the filament 53 follows is referred to as a course C. In one embodiment, the second material 58 is a strand 58 that is interlaced or woven into the chain of loops 55, where the strand 58 is provided to limit the elongation of the knitted loops in the band 51. In one embodiment, the bands 51 and the strand 58 are each attached on opposing ends between the proximal support 54 and the distal support 56, and when the band 51 is stretched, the strand 58 stops the elongation of the band 51 at the desired length L2.
FIG. 4D illustrates the strand 58 stopping the elongation of the device 50 at the final length L2 that is substantially equal to the affected length of an erect Peyronie's affected penis.
FIG. 5 is a top view of one embodiment of a Peyronie's treatment device 60 (device 60). The device 60 is provided with multiple bands 61 having elastic material 62 extending between a proximal support 64 that is attachable to a base of a penis and a distal support 66 that is attachable adjacent a corona of the penis, and a second material 68 attached to the elastic material 62 that is provided to stop elongation of the elastic material 62 at a length approximately equal to the affected length of a Peyronie's affected erect penis.
In one embodiment, the proximal support 64 is provided as a continuous ring that is attachable around an entire circumference of the base of the penis P and the distal support 66 is provided as a continuous ring that is attachable around an entire circumference of the penis adjacent the corona.
FIG. 6 is a block diagram 70 of one embodiment of a method of treating Peyronie's disease. The method of treatment includes at 72 providing an elastic device that is attachable subcutaneously to the penis. The method of treatment includes at 74 providing the elastic device with a stretch stop that limits the elongation of the device to a distance that is approximately equal to the affected length of a Peyronie's afflicted erect penis (see FIG. 3A).
FIG. 7 is a block diagram 80 of one embodiment of a method of treating Peyronie's disease. The method of treatment includes at 82 evaluating curvature and a shortened length of an erect penis of a patient afflicted by Peyronie's disease. The method of treatment includes at 84 selecting an elastic device having a stretch stop that limits the elongation of the elastic device to approximately the shortened length of the erect penis. The method of treatment includes at 86 attaching the elastic device to a side of the penis, subcutaneously to the tunica albuginea, opposite the side of the penis having the curvature. The method of treatment includes at 88 configuring the elastic device to stretch with the erection of the penis and configuring the stretch stop to apply tension to the side of the penis having the curvature, thus reducing the curvature of the erect penis.
Example
The following example illustrates, with reference to FIG. 3A, the surgical placement of one of the Peyronie's treatment devices described above without degloving the penile skin.
The patient is anesthetized and surgically draped to define a sterile operating field in an appropriate manner.
The surgeon forms a circumcoronal incision adjacent to the glans penis and a penoscrotal incision adjacent to the base of the penis P. The dartos fascia is reflected to expose the Buck's fascia, and the Buck's fascia is incised down to the tunica albuginea.
The surgeon introduces a flat-bladed tool subcutaneous to the penis over the tunica albuginea and forms a pathway extending from the penoscrotal incision to the circumcoronal incision along the unaffected side 42 of the penis P.
In one embodiment, an artificial erection is imparted to the penis P with an intracavernous injection of saline solution and the surgeon proceeds to attach one of the above-described Peyronie's treatment devices to an exterior surface of the tunica albuginea on a contralateral side of the penis opposite the side on which the Peyronie's plaques have formed.
The proximal support 24 is attached to the base of the penis P, for example with one or more sutures. The flat-bladed tool, or a forceps, is employed to deliver the distal support 26 to a location adjacent a corona of the penis. The surgeon corrects the curvature in the penis P (e.g., manually) and attaches the distal support 26 to the penis at a location that conforms the unaffected side 42 of the penis P to have a length that approximates a length of the affected side 40 of the penis P. In this manner, the implanted Peyronie's treatment device corrects the curvature in the penis.
Although specific embodiments have been illustrated and described herein, it will be appreciated by those of ordinary skill in the art that a variety of alternate and/or equivalent implementations may be substituted for the specific embodiments shown and described without departing from the scope of the present invention. This application is intended to cover any adaptations or variations of medical devices as discussed herein. Therefore, it is intended that this invention be limited only by the claims and the equivalents thereof.

Claims (5)

What is claimed is:
1. A method of treating Peyronie's disease manifested in an erect penis having a first penis side with an unaffected length and a second penis side with an affected length that is shorter than the unaffected length, the method comprising:
attaching an elastic device subcutaneously to the first penis side; and
providing the elastic device with a stretch stop that limits elongation of the first penis side to an erection distance that is approximately equal to the affected length of the erect penis.
2. The method of claim 1, comprising attaching the elastic device subcutaneously to the first penis side between external skin of the penis and a tunica albuginea of the penis.
3. The method of claim 1, comprising providing an elastic band connected between a proximal support that is attachable to a base of the penis and a distal support that is attachable adjacent a corona of the penis.
4. The method of claim 3, comprising providing the elastic band with a second material that is attached to the elastic band, the second material configured to stop elongation of the elastic band.
5. A method of treating Peyronie's disease manifested in an erect penis having a first penis side with an unaffected length and a second penis side with an affected length that is shorter than the unaffected length, the method comprising:
incising skin on the first penis side and accessing the tunica albuginea;
creating an artificial erection in the penis;
attaching a proximal end of an elastic device to a base of the penis on the first penis side;
straightening the penis to reduce a curvature in the erect penis; and
attaching a distal end of the elastic device adjacent to a corona of the penis on the first penis side to maintain the reduced curvature in the erect penis;
wherein the elastic device includes a stretch stop that limits elongation of the first penis side to an erection distance that is approximately equal to the affected length of the erect penis.
US12/954,633 2010-11-24 2010-11-25 Method of treating Peyronie's disease Active 2031-07-12 US8465413B2 (en)

Priority Applications (5)

Application Number Priority Date Filing Date Title
US12/954,633 US8465413B2 (en) 2010-11-25 2010-11-25 Method of treating Peyronie's disease
US13/189,580 US8206282B2 (en) 2010-11-24 2011-07-25 Peyronie's treatment device
EP11794630.1A EP2642949B1 (en) 2010-11-24 2011-11-24 Peyronie's treatment device
PCT/DK2011/050448 WO2012069060A1 (en) 2010-11-24 2011-11-24 Peyronie's treatment device
ES11794630.1T ES2560629T3 (en) 2010-11-24 2011-11-24 Peyronie's disease treatment device and Peyronie's disease treatment method

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US12/954,633 US8465413B2 (en) 2010-11-25 2010-11-25 Method of treating Peyronie's disease

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US13/189,580 Continuation US8206282B2 (en) 2010-11-24 2011-07-25 Peyronie's treatment device

Publications (2)

Publication Number Publication Date
US20120136206A1 US20120136206A1 (en) 2012-05-31
US8465413B2 true US8465413B2 (en) 2013-06-18

Family

ID=46127063

Family Applications (1)

Application Number Title Priority Date Filing Date
US12/954,633 Active 2031-07-12 US8465413B2 (en) 2010-11-24 2010-11-25 Method of treating Peyronie's disease

Country Status (1)

Country Link
US (1) US8465413B2 (en)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10729403B2 (en) 2010-12-14 2020-08-04 Hologic, Inc. System and method for fusing three dimensional image data from a plurality of different imaging systems for use in diagnostic imaging
US10956701B2 (en) 2016-05-27 2021-03-23 Hologic, Inc. Synchronized surface and internal tumor detection

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104096157A (en) * 2014-07-15 2014-10-15 王子锋 Traditional Chinese medicine for treating induration of penis and preparation method thereof
US20180177625A1 (en) * 2016-11-22 2018-06-28 Wei Zhang Apparatus and method for treating male impotence
WO2020102120A1 (en) * 2018-11-16 2020-05-22 Lamamed Solutions Systems and methods for providing penile modeling

Citations (76)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4175554A (en) 1978-03-16 1979-11-27 Gerow Frank J Prosthesis of male impotence
US4338300A (en) 1981-02-05 1982-07-06 The Regents Of The University Of California Use of purified clostridial collangenase in the treatment of Peyronie's disease
AU2855189A (en) 1988-01-25 1989-07-27 Baker Cummins Dermatologicals, Inc. Method of treating fibrotic disorders
CA2352552A1 (en) 1990-04-25 1991-10-26 Virgil A. Place Treatment of erectile dysfunction
US5094230A (en) 1991-09-19 1992-03-10 Clark Jr Buford E Method and apparatus for treating Peyronie's disease
CA2137378A1 (en) 1992-06-05 1993-12-23 Stephen Brian Henry Kent D-enzyme compositions and methods of their use
US5312621A (en) 1988-01-25 1994-05-17 Baker Cummins Dermatologicals, Inc. Method of treating fibrotic disorders
US5366729A (en) 1989-09-15 1994-11-22 Symbicom Aktiebolag Non-glycosylated variants of extracellular superoxide dismutase (EC-SOD)
CA2186382A1 (en) 1994-03-25 1995-10-05 Virgil A. Place Method and apparatus for diagnosing erectile dysfunction
CA2204493A1 (en) 1994-11-04 1996-05-17 Hermann Katinger Application of superoxide dismutase in liposomes
FR2727855A1 (en) 1994-12-08 1996-06-14 Subrini Louis CAVERNOR EXTENSION IMPLANTS
US5628329A (en) 1995-07-26 1997-05-13 Boyd B. Bennett Methods and apparatus for obtaining and maintaining penile erection
US5782621A (en) 1996-04-22 1998-07-21 Mission Pharmacal Company Manual pump with inherent vacuum limit
US5836864A (en) 1996-08-07 1998-11-17 Clark, Jr.; Roland T. Penile lengthening traction device
BR9801985A (en) 1998-04-30 2000-02-08 Cristiano Alberto Ribeiro Sant Creamy composition applied in the therapy of peyronie's disease.
US6022539A (en) 1999-06-03 2000-02-08 Advance Biofactures Of Curacao Amelioration of peyronie's disease
CA2339003A1 (en) 1998-08-03 2000-02-17 W. Jerry Easterling Composition and method for treating peyronie's disease and other sub-dermal plaque manifestation disorders
US6033374A (en) 1998-01-08 2000-03-07 Miller, Jr.; Stanley J. Penile traction device
US6113939A (en) 1990-04-25 2000-09-05 Vivus, Inc. Pharmaceutical compositions for treating priapism and peyronie's syndrome
CA2366750A1 (en) 1999-04-02 2000-10-12 Temple University - Of The Commonwealth System Of Higher Education (e)-styryl sulfone anticancer agents
BR0101823A (en) 2001-04-10 2001-09-25 Cristiano Alberto Ribeiro Sant Pharmaceutical composition applied in the treatment of peyronie's disease, collagenosis and fibrotic pathologies based on vitamin-e, bromelain and hyaluronity
BR0006719A (en) 2000-05-04 2001-09-25 Cristiano Alberto Ribeiro Sant Composition in the form of cream, gel and cream gel applied in the treatment of peyronie's disease, collagen and fibrotic pathologies based on vitamin-e, papain 2% and hyaluronidase
US6303126B1 (en) 1994-04-28 2001-10-16 Toshikazu Nakamura Treatment of fibrosis by HGF
CA2443018A1 (en) 2001-04-06 2002-10-17 Cristiano Alberto Ribeiro Santana Papaine containing pharmaceutical formulation resp. its use
ITRM20010695A1 (en) 2001-11-26 2003-05-26 Sigma Tau Ind Farmaceuti USE OF PROPIONIL L-CARNITINE OR ITS PHARMACOLOGICALLY ACCEPTABLE SALT FOR THE PREPARATION OF A MEDICATION FOR THE TREATMENT OF
ES2197018A1 (en) 2002-06-06 2003-12-16 Esp Farmaceuticas Centrum Sa Novel therapeutic use of polypodium extracts
US20040018958A1 (en) 2002-07-25 2004-01-29 Yih-Lin Chung Methods for therapy of radiation cutaneous syndrome
US20040043026A1 (en) 2002-05-13 2004-03-04 Tai-Lan Tuan Treatment and prevention of abnormal scar formation in keloids and other cutaneous or internal wounds or lesions
US20040077970A1 (en) 2002-10-16 2004-04-22 Julian Osbon Method, system and kit for treatment of peyronie's disease
CA2509241A1 (en) 2002-12-23 2004-07-15 William Marsh Rice University Use of serum amyloid p (sap) and related compositions for the suppression of fibrosis-related diseases
US20040146496A1 (en) 2003-01-23 2004-07-29 Mcmichael John Method of treatment of connective tissue disorders by administration of streptolysin O
WO2004069866A1 (en) 2003-02-10 2004-08-19 Autogen Research Pty Ltd Therapeutic molecules
RU2234257C2 (en) 2002-11-01 2004-08-20 Сокольщик Михаил Миронович Method for surgical correction oferectile deformation in case of peyronie's disease
EA004801B1 (en) 2002-08-01 2004-08-26 Гурам Михайлович Пичхадзе Method of treating peyronie's disease
WO2004086981A1 (en) 2003-03-31 2004-10-14 Egydio Paulo H Surgical method and auxiliary device to correct penis curvature
WO2005003351A1 (en) 2003-07-08 2005-01-13 Chemgenex Pharmaceuticals Limited Differential expression of nucleic acid molecules
WO2005004906A2 (en) 2003-07-08 2005-01-20 Imtm Gmbh Use of dp iv and apn inhibitors for the treatment of dermatological diseases involving the hyperproliferation and modified differentiation conditions of fibroblasts
US20050020569A1 (en) 1998-08-03 2005-01-27 Easterling W. Jerry Composition and method for treating erectile dysfunction and reducing fibrosis in erectile tissue of the human penis
US20050025804A1 (en) 2003-07-28 2005-02-03 Adam Heller Reduction of adverse inflammation
WO2005014634A1 (en) 2003-08-12 2005-02-17 Agt Biosciences Limited A gene and uses therefor
AU2004279475A1 (en) 2003-10-10 2005-04-21 Alchemia Oncology Pty Limited The moduilation of hyaluronan synthesis and degradation in the treatment of disease
CA2541438A1 (en) 2003-10-10 2005-04-21 Meditech Research Limited The modulation of hyaluronan synthesis and degradation in the treatment of disease
US20050085486A1 (en) 2003-10-21 2005-04-21 Gonzalez-Cadavid Nestor F. Methods of use of inhibitors of phosphodiesterases and modulators of nitric oxide, reactive oxygen species, and metalloproteinases in the treatment of peyronie's disease, arteriosclerosis and other fibrotic diseases
BR0304395A (en) 2003-03-20 2005-05-03 Adel Barreto Pulsing current source thermoelectric capsule, thermoelectric wedge and thermoelectric blanket
RU2256405C1 (en) 2003-11-18 2005-07-20 Диагностический центр "Здоровье" Method of finding tactics of shock-wave therapy at peyronie's disease
CA2536096A1 (en) 2004-01-30 2005-08-18 Angiotech International Ag Compositions and methods for treating contracture
US20050192210A1 (en) 2004-03-01 2005-09-01 Rothbard Jonathan B. Compositions and methods for treating diseases
EP1574213A1 (en) 2004-03-11 2005-09-14 Yih-Lin Chung Use of histone deacetylase inhibitors for increasing therapeutic gain in radiotherapy and chemotherapy
AU2005253966A1 (en) 2004-06-08 2005-12-29 Temple University Of The Commonwealth System Of Higher Education Heteroaryl sulfones and sulfonamides and therapeutic uses thereof
CA2575907A1 (en) 2004-08-06 2006-02-16 Bayer Healthcare Ag Novel uses of 2-phenyl-substituted imidazotriazinone derivatives
CA2618939A1 (en) 2004-08-13 2006-04-27 Jaguar Bioscience Inc. Systems and methods for identifying diagnostic indicators
US7056953B2 (en) 1999-04-02 2006-06-06 Temple University - Of The Commonwealth System Of Higher Education (E)-styryl sulfone anticancer agents
CA2498639A1 (en) 2005-03-02 2006-09-02 J.D. Globus Niacin used as oral supplementation for the treatment and prevention of sexual dysfunction in human males and females
BRPI0601884A (en) 2006-05-08 2006-09-26 Cristiano Alberto Ribe Santana pharmaceutical composition applicable to the treatment of peyronie disease and its method of obtaining
US20060228358A1 (en) 2003-02-13 2006-10-12 Lawson Alastair D G Antibody molecules having specificity for human il-1 beta
WO2006123226A2 (en) 2005-05-18 2006-11-23 De Villiers, Malan An inhibitor of mtor for inhibiting the formation of scar tissue
AU2006259113A1 (en) 2005-06-17 2006-12-21 Nycomed Gmbh Use of PDE1C and inhibitors thereof
AU2006269488A1 (en) 2005-07-07 2007-01-18 Genzyme Corporation AAV vectors encoding superoxide dismutase
US20070044163A1 (en) 2003-06-20 2007-02-22 Fagan Richard J Interferon gamma-like protein
US20070065368A1 (en) 2002-12-23 2007-03-22 William Marsh Rice University Compositions and Methods for Suppressing Fibrocytes and for Detecting Fibrocyte Differentiation
US20070065866A1 (en) 2002-12-23 2007-03-22 William Marsh Rice University Compositions and Methods for Suppressing Fibrocytes
CA2627873A1 (en) 2005-10-31 2007-05-10 Scott Wilhelm Treatment of cancer with sorafenib
WO2007059119A2 (en) 2005-11-11 2007-05-24 Ivan Borozan Systems and methods for identifying diagnostic indicators
US20070129600A1 (en) 2002-10-16 2007-06-07 Augusta Medical Sytems, Inc. Kit, system and method to treat erectile dysfunction
AU2006320162A1 (en) 2005-12-02 2007-06-07 The Johns Hopkins University Use of high-dose oxazaphosphorine drugs for treating immune disorders
WO2007066082A1 (en) 2005-12-09 2007-06-14 Ucb Pharma S.A. Antibody molecules having specificity for human il-6
WO2007093409A2 (en) 2006-02-14 2007-08-23 Noxxon Pharma Ag Mcp-i binding nucleic acids
US20070213681A1 (en) 2006-03-09 2007-09-13 Misonix, Incorporated Method for the treatment of peyronie's disease
US20070219119A1 (en) 2003-01-23 2007-09-20 Milkhaus Laboratory, Inc. Method of Treatment of Tendonitis by Administration of Streptolysin O
WO2008016682A2 (en) 2006-08-02 2008-02-07 Temple University - Of The Commonwealth System Of Higher Education Aryl vinyl sulfides, sulfones, sulfoxides and sulfonamides, derivatives thereof and therapeutic uses thereof
WO2008020027A2 (en) 2006-08-16 2008-02-21 Action Medicines, S.L. 2,5-dihydroxybenzene compounds for the treatment of skin cancer
US20080107646A1 (en) 2002-04-26 2008-05-08 Yih-Lin Chung Method for ameliorating pruritus
WO2008060783A2 (en) 2006-10-05 2008-05-22 Centocor Ortho Biotech Inc. Ccr2 antagonists for treatment of fibrosis
RU2326602C1 (en) 2006-12-07 2008-06-20 Игорь Гарриевич Таруашвили Method of penis intra-cavernous prosthetics
WO2008076270A2 (en) 2006-12-13 2008-06-26 Temple University-Of The Commonwealth System Of Higher Education Sulfide, sulfoxide and sulfone chalcone analogues, derivatives thereof and therapeutic uses thereof
US20100130816A1 (en) 2008-11-26 2010-05-27 Vladimir Gekhter Expandable external penile support device (eepsd) with attachments and method of manufacturing

Patent Citations (126)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4175554A (en) 1978-03-16 1979-11-27 Gerow Frank J Prosthesis of male impotence
US4338300A (en) 1981-02-05 1982-07-06 The Regents Of The University Of California Use of purified clostridial collangenase in the treatment of Peyronie's disease
US5312621A (en) 1988-01-25 1994-05-17 Baker Cummins Dermatologicals, Inc. Method of treating fibrotic disorders
AU2855189A (en) 1988-01-25 1989-07-27 Baker Cummins Dermatologicals, Inc. Method of treating fibrotic disorders
US5366729A (en) 1989-09-15 1994-11-22 Symbicom Aktiebolag Non-glycosylated variants of extracellular superoxide dismutase (EC-SOD)
CA2040914A1 (en) 1990-04-25 1991-10-26 Virgil A. Place Treatment of erectile dysfunction
US6113939A (en) 1990-04-25 2000-09-05 Vivus, Inc. Pharmaceutical compositions for treating priapism and peyronie's syndrome
CA2352552A1 (en) 1990-04-25 1991-10-26 Virgil A. Place Treatment of erectile dysfunction
US5094230A (en) 1991-09-19 1992-03-10 Clark Jr Buford E Method and apparatus for treating Peyronie's disease
CA2137378A1 (en) 1992-06-05 1993-12-23 Stephen Brian Henry Kent D-enzyme compositions and methods of their use
US7135279B2 (en) 1992-06-05 2006-11-14 The Scripps Research Institute D-enzyme compositions and methods of their use
CA2186382A1 (en) 1994-03-25 1995-10-05 Virgil A. Place Method and apparatus for diagnosing erectile dysfunction
US5769088A (en) 1994-03-25 1998-06-23 Vivus, Inc. Process and kits for diagnosing erectile dysfunction, and related methods of treatment
US6303126B1 (en) 1994-04-28 2001-10-16 Toshikazu Nakamura Treatment of fibrosis by HGF
CA2204493A1 (en) 1994-11-04 1996-05-17 Hermann Katinger Application of superoxide dismutase in liposomes
US6312720B1 (en) 1994-11-04 2001-11-06 Polymun Scientific Immunbiogische Forschung Gmbh Liposomal recombinant human superoxide-dismutase for the treatment of peyronie's disease
FR2727855A1 (en) 1994-12-08 1996-06-14 Subrini Louis CAVERNOR EXTENSION IMPLANTS
US5788627A (en) 1994-12-08 1998-08-04 Subrini; Louis Cavernosal extension implants
US5628329A (en) 1995-07-26 1997-05-13 Boyd B. Bennett Methods and apparatus for obtaining and maintaining penile erection
US5782621A (en) 1996-04-22 1998-07-21 Mission Pharmacal Company Manual pump with inherent vacuum limit
US5836864A (en) 1996-08-07 1998-11-17 Clark, Jr.; Roland T. Penile lengthening traction device
US6033374A (en) 1998-01-08 2000-03-07 Miller, Jr.; Stanley J. Penile traction device
BR9801985A (en) 1998-04-30 2000-02-08 Cristiano Alberto Ribeiro Sant Creamy composition applied in the therapy of peyronie's disease.
CA2339003A1 (en) 1998-08-03 2000-02-17 W. Jerry Easterling Composition and method for treating peyronie's disease and other sub-dermal plaque manifestation disorders
US20050020569A1 (en) 1998-08-03 2005-01-27 Easterling W. Jerry Composition and method for treating erectile dysfunction and reducing fibrosis in erectile tissue of the human penis
CA2366750A1 (en) 1999-04-02 2000-10-12 Temple University - Of The Commonwealth System Of Higher Education (e)-styryl sulfone anticancer agents
US7056953B2 (en) 1999-04-02 2006-06-06 Temple University - Of The Commonwealth System Of Higher Education (E)-styryl sulfone anticancer agents
US6022539A (en) 1999-06-03 2000-02-08 Advance Biofactures Of Curacao Amelioration of peyronie's disease
US20030161821A1 (en) 2000-05-04 2003-08-28 Santana Ribeiro Cristiano Alberto Pharmaceutical composition
BR0006719A (en) 2000-05-04 2001-09-25 Cristiano Alberto Ribeiro Sant Composition in the form of cream, gel and cream gel applied in the treatment of peyronie's disease, collagen and fibrotic pathologies based on vitamin-e, papain 2% and hyaluronidase
US20040146494A1 (en) 2001-04-06 2004-07-29 Santana Cristiano Alberto Ribeiro Papaine containing pharmaceutical formulation resp its use
CA2443018A1 (en) 2001-04-06 2002-10-17 Cristiano Alberto Ribeiro Santana Papaine containing pharmaceutical formulation resp. its use
BR0101823A (en) 2001-04-10 2001-09-25 Cristiano Alberto Ribeiro Sant Pharmaceutical composition applied in the treatment of peyronie's disease, collagenosis and fibrotic pathologies based on vitamin-e, bromelain and hyaluronity
ITRM20010695A1 (en) 2001-11-26 2003-05-26 Sigma Tau Ind Farmaceuti USE OF PROPIONIL L-CARNITINE OR ITS PHARMACOLOGICALLY ACCEPTABLE SALT FOR THE PREPARATION OF A MEDICATION FOR THE TREATMENT OF
US20050038044A1 (en) 2001-11-26 2005-02-17 Aleardo Koverech Use of propionyl-carnitine or one of its pharmacologically acceptable salts for the preparation of a medicine for the treatment of la peyronie's disease
US20080107646A1 (en) 2002-04-26 2008-05-08 Yih-Lin Chung Method for ameliorating pruritus
US20040043026A1 (en) 2002-05-13 2004-03-04 Tai-Lan Tuan Treatment and prevention of abnormal scar formation in keloids and other cutaneous or internal wounds or lesions
ES2197018A1 (en) 2002-06-06 2003-12-16 Esp Farmaceuticas Centrum Sa Novel therapeutic use of polypodium extracts
US20060093690A1 (en) 2002-06-06 2006-05-04 Especialidades Farmaceuticas Centrum, S.A. Novel therapeutic use of polypodium extracts
US20040018958A1 (en) 2002-07-25 2004-01-29 Yih-Lin Chung Methods for therapy of radiation cutaneous syndrome
EA004801B1 (en) 2002-08-01 2004-08-26 Гурам Михайлович Пичхадзе Method of treating peyronie's disease
US20070129600A1 (en) 2002-10-16 2007-06-07 Augusta Medical Sytems, Inc. Kit, system and method to treat erectile dysfunction
US20040077970A1 (en) 2002-10-16 2004-04-22 Julian Osbon Method, system and kit for treatment of peyronie's disease
RU2234257C2 (en) 2002-11-01 2004-08-20 Сокольщик Михаил Миронович Method for surgical correction oferectile deformation in case of peyronie's disease
CA2509392A1 (en) 2002-12-23 2004-07-15 William Marsh Rice University Methods of detecting the inhibition of fibrocyte formation and methods and compositions for enhancing fibrocyte formation
CA2509241A1 (en) 2002-12-23 2004-07-15 William Marsh Rice University Use of serum amyloid p (sap) and related compositions for the suppression of fibrosis-related diseases
WO2004059318A2 (en) 2002-12-23 2004-07-15 William Marsh Rice University Methods of detecting the inhibition of fibrocyte formation and methods and compositions for enhancing fibrocyte formation
WO2004058292A2 (en) 2002-12-23 2004-07-15 William Marsh Rice University Methods and compositions for suppressing fibrocyte differentiation
US20070065368A1 (en) 2002-12-23 2007-03-22 William Marsh Rice University Compositions and Methods for Suppressing Fibrocytes and for Detecting Fibrocyte Differentiation
US20070065866A1 (en) 2002-12-23 2007-03-22 William Marsh Rice University Compositions and Methods for Suppressing Fibrocytes
US20070219119A1 (en) 2003-01-23 2007-09-20 Milkhaus Laboratory, Inc. Method of Treatment of Tendonitis by Administration of Streptolysin O
US20040146496A1 (en) 2003-01-23 2004-07-29 Mcmichael John Method of treatment of connective tissue disorders by administration of streptolysin O
WO2004069866A1 (en) 2003-02-10 2004-08-19 Autogen Research Pty Ltd Therapeutic molecules
CA2514071A1 (en) 2003-02-10 2004-08-19 Autogen Research Pty Ltd Therapeutic molecules
AU2004210013A1 (en) 2003-02-10 2004-08-19 Autogen Research Pty Ltd Therapeutic molecules
US20070135335A1 (en) 2003-02-10 2007-06-14 Autogen Research Pty Ltd. Therapeutic molecules
US20060228358A1 (en) 2003-02-13 2006-10-12 Lawson Alastair D G Antibody molecules having specificity for human il-1 beta
BR0304395A (en) 2003-03-20 2005-05-03 Adel Barreto Pulsing current source thermoelectric capsule, thermoelectric wedge and thermoelectric blanket
WO2004086981A1 (en) 2003-03-31 2004-10-14 Egydio Paulo H Surgical method and auxiliary device to correct penis curvature
US20100256444A1 (en) * 2003-03-31 2010-10-07 Egydio Paulo H Surgical method and auxiliary device to correct penis curvature
US7780591B2 (en) * 2003-03-31 2010-08-24 Egydio Paulo H Surgical method and auxiliary device to correct penis curvature
US20070016107A1 (en) 2003-03-31 2007-01-18 Egydio Paulo H Surgical method and auxiliary device to correct penis curvature
US20070044163A1 (en) 2003-06-20 2007-02-22 Fagan Richard J Interferon gamma-like protein
WO2005003351A1 (en) 2003-07-08 2005-01-13 Chemgenex Pharmaceuticals Limited Differential expression of nucleic acid molecules
WO2005004906A2 (en) 2003-07-08 2005-01-20 Imtm Gmbh Use of dp iv and apn inhibitors for the treatment of dermatological diseases involving the hyperproliferation and modified differentiation conditions of fibroblasts
US20060228775A1 (en) 2003-07-08 2006-10-12 Chemgenex Pharmaceuticals Llimited Differential expression of nucleic acid molecules
US20070042938A1 (en) 2003-07-08 2007-02-22 Siegfried Ansorge Use of dpiv and apn inhibitors for the treatment of dermatalogical diseases involving the hyperproliferation and modified differentiation conditions of fibroblasts
US20050025804A1 (en) 2003-07-28 2005-02-03 Adam Heller Reduction of adverse inflammation
US20050025805A1 (en) 2003-07-28 2005-02-03 Adam Heller Osmium compounds for reduction of adverse inflammation
WO2005014634A1 (en) 2003-08-12 2005-02-17 Agt Biosciences Limited A gene and uses therefor
AU2004279475A1 (en) 2003-10-10 2005-04-21 Alchemia Oncology Pty Limited The moduilation of hyaluronan synthesis and degradation in the treatment of disease
CA2541438A1 (en) 2003-10-10 2005-04-21 Meditech Research Limited The modulation of hyaluronan synthesis and degradation in the treatment of disease
US20070286856A1 (en) 2003-10-10 2007-12-13 Alchemia Oncology Limited Modulation of Hyaluronan Synthesis and Degradation in the Treatment of Disease
WO2005035548A1 (en) 2003-10-10 2005-04-21 Meditech Research Limited The moduilation of hyaluronan synthesis and degradation in the treatment of disease
US20050085486A1 (en) 2003-10-21 2005-04-21 Gonzalez-Cadavid Nestor F. Methods of use of inhibitors of phosphodiesterases and modulators of nitric oxide, reactive oxygen species, and metalloproteinases in the treatment of peyronie's disease, arteriosclerosis and other fibrotic diseases
RU2256405C1 (en) 2003-11-18 2005-07-20 Диагностический центр "Здоровье" Method of finding tactics of shock-wave therapy at peyronie's disease
US20050186261A1 (en) 2004-01-30 2005-08-25 Angiotech International Ag Compositions and methods for treating contracture
CA2536096A1 (en) 2004-01-30 2005-08-18 Angiotech International Ag Compositions and methods for treating contracture
WO2005074913A2 (en) 2004-01-30 2005-08-18 Angiotech International Ag Compositions and methods for treating contracture
AU2005210668A1 (en) 2004-01-30 2005-08-18 Angiotech International Ag Compositions and methods for treating contracture
US20050192210A1 (en) 2004-03-01 2005-09-01 Rothbard Jonathan B. Compositions and methods for treating diseases
US20070185203A1 (en) 2004-03-01 2007-08-09 Rothbard Jonathan B Compositions and Methods for Treating Diseases
EP1574213A1 (en) 2004-03-11 2005-09-14 Yih-Lin Chung Use of histone deacetylase inhibitors for increasing therapeutic gain in radiotherapy and chemotherapy
AU2005253966A1 (en) 2004-06-08 2005-12-29 Temple University Of The Commonwealth System Of Higher Education Heteroaryl sulfones and sulfonamides and therapeutic uses thereof
CA2569705A1 (en) 2004-06-08 2005-12-29 Temple University - Of The Commonwealth System Of Higher Education Heteroaryl sulfones and sulfonamides and therapeutic uses thereof
WO2005123077A2 (en) 2004-06-08 2005-12-29 Temple University-Of The Commonwealth System Of Higher Education Heteroaryl sulfones and sulfonamides and therapeutic uses thereof
US20070232649A1 (en) 2004-06-08 2007-10-04 Temple University-Of The Commonwealth System Of Higher Education Heteroaryl Sulfones and Sulfonamides and Therapeutic Uses Thereof
AU2005270446A1 (en) 2004-08-06 2006-02-16 Bayer Healthcare Ag Novel uses of 2-phenyl-substituted imidazotriazinone derivatives
WO2006015715A1 (en) 2004-08-06 2006-02-16 Bayer Healthcare Ag Novel uses of 2-phenyl-substituted imidazotriazinone derivatives
CA2575907A1 (en) 2004-08-06 2006-02-16 Bayer Healthcare Ag Novel uses of 2-phenyl-substituted imidazotriazinone derivatives
US20070299088A1 (en) 2004-08-06 2007-12-27 Bayer Healthcare Ag Novel Uses of 2-Phenyl-Substituted Imidazotriazinone Derivatives
CA2618939A1 (en) 2004-08-13 2006-04-27 Jaguar Bioscience Inc. Systems and methods for identifying diagnostic indicators
US20060177837A1 (en) 2004-08-13 2006-08-10 Ivan Borozan Systems and methods for identifying diagnostic indicators
WO2006044017A2 (en) 2004-08-13 2006-04-27 Jaguar Bioscience Inc. Systems and methods for identifying diagnostic indicators
CA2498639A1 (en) 2005-03-02 2006-09-02 J.D. Globus Niacin used as oral supplementation for the treatment and prevention of sexual dysfunction in human males and females
WO2006123226A2 (en) 2005-05-18 2006-11-23 De Villiers, Malan An inhibitor of mtor for inhibiting the formation of scar tissue
CA2611386A1 (en) 2005-06-17 2006-12-21 Nycomed Gmbh Use of pde1c and inhibitors thereof
AU2006259113A1 (en) 2005-06-17 2006-12-21 Nycomed Gmbh Use of PDE1C and inhibitors thereof
WO2006134101A2 (en) 2005-06-17 2006-12-21 Nycomed Gmbh Use of pde1c and inhibitors thereof
US20080181872A1 (en) 2005-07-07 2008-07-31 Mohammad Doroudchi Aav vectors encoding superoxide dismutase
WO2007008486A2 (en) 2005-07-07 2007-01-18 Genzyme Corporation Aav vectors encoding superoxide dismutase
AU2006269488A1 (en) 2005-07-07 2007-01-18 Genzyme Corporation AAV vectors encoding superoxide dismutase
WO2007053573A2 (en) 2005-10-31 2007-05-10 Bayer Pharmaceuticals Corporation Treatment of cancer with sorafenib
CA2627873A1 (en) 2005-10-31 2007-05-10 Scott Wilhelm Treatment of cancer with sorafenib
WO2007059119A2 (en) 2005-11-11 2007-05-24 Ivan Borozan Systems and methods for identifying diagnostic indicators
AU2006320162A1 (en) 2005-12-02 2007-06-07 The Johns Hopkins University Use of high-dose oxazaphosphorine drugs for treating immune disorders
WO2007065167A1 (en) 2005-12-02 2007-06-07 The Johns Hopkins University Use of high-dose oxazaphosphorine drugs for treating immune disorders
US20070202077A1 (en) 2005-12-02 2007-08-30 Brodsky Robert A Use of High-Dose Oxazaphosphorine Drugs for Treating Immune Disorders
US20070154481A1 (en) 2005-12-09 2007-07-05 Gelinas Richard E Antibody Molecules Having Specificity For Human IL-6
WO2007066082A1 (en) 2005-12-09 2007-06-14 Ucb Pharma S.A. Antibody molecules having specificity for human il-6
AU2006323490A1 (en) 2005-12-09 2007-06-14 R-Pharm International Llc Antibody molecules having specificity for human IL-6
WO2007093409A2 (en) 2006-02-14 2007-08-23 Noxxon Pharma Ag Mcp-i binding nucleic acids
AU2007214668A1 (en) 2006-02-14 2007-08-23 TME Pharma AG MCP-I binding nucleic acids
US20070213681A1 (en) 2006-03-09 2007-09-13 Misonix, Incorporated Method for the treatment of peyronie's disease
BRPI0601884A (en) 2006-05-08 2006-09-26 Cristiano Alberto Ribe Santana pharmaceutical composition applicable to the treatment of peyronie disease and its method of obtaining
WO2008016682A2 (en) 2006-08-02 2008-02-07 Temple University - Of The Commonwealth System Of Higher Education Aryl vinyl sulfides, sulfones, sulfoxides and sulfonamides, derivatives thereof and therapeutic uses thereof
WO2008020030A1 (en) 2006-08-16 2008-02-21 Action Medicines, S.L. 2,5-dihydroxybenzene compounds for the treatment of psoriasis
WO2008020040A2 (en) 2006-08-16 2008-02-21 Action Medicines, S.L. 2,5-dihydroxybenzene compounds for the treatment of fibrosis
US20080125486A1 (en) 2006-08-16 2008-05-29 Action Medicines Use of 2,5-Dihydroxybenzene Compounds and Derivatives for the Treatment of Hematological Dyscrasias and Cancer of an Organ
WO2008020039A2 (en) 2006-08-16 2008-02-21 Action Medicines, S.L. 2,5-dihydroxybenzene compounds for treating cancers and hematological dyscrasias
WO2008020028A1 (en) 2006-08-16 2008-02-21 Action Medicines, S.L. 2,5 dihydroxybenzene compounds for the treatment of rosacea
WO2008020027A2 (en) 2006-08-16 2008-02-21 Action Medicines, S.L. 2,5-dihydroxybenzene compounds for the treatment of skin cancer
WO2008060783A2 (en) 2006-10-05 2008-05-22 Centocor Ortho Biotech Inc. Ccr2 antagonists for treatment of fibrosis
RU2326602C1 (en) 2006-12-07 2008-06-20 Игорь Гарриевич Таруашвили Method of penis intra-cavernous prosthetics
WO2008076270A2 (en) 2006-12-13 2008-06-26 Temple University-Of The Commonwealth System Of Higher Education Sulfide, sulfoxide and sulfone chalcone analogues, derivatives thereof and therapeutic uses thereof
US20100130816A1 (en) 2008-11-26 2010-05-27 Vladimir Gekhter Expandable external penile support device (eepsd) with attachments and method of manufacturing

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10729403B2 (en) 2010-12-14 2020-08-04 Hologic, Inc. System and method for fusing three dimensional image data from a plurality of different imaging systems for use in diagnostic imaging
US11730442B2 (en) 2010-12-14 2023-08-22 Hologic, Inc. System and method for fusing three dimensional image data from a plurality of different imaging systems for use in diagnostic imaging
US10956701B2 (en) 2016-05-27 2021-03-23 Hologic, Inc. Synchronized surface and internal tumor detection

Also Published As

Publication number Publication date
US20120136206A1 (en) 2012-05-31

Similar Documents

Publication Publication Date Title
US9615905B2 (en) Male urethral prosthesis with tensioning member
US20190307495A1 (en) Surgical implant for correction of hallux valgus or tailor's bunion
US8465413B2 (en) Method of treating Peyronie's disease
US3832996A (en) Endoprosthesis for the penis and a method of endoprosthetic repair
EP3151766B1 (en) Surgical implant for correction of hallux valgus or tailor's bunion
WO2007109759A2 (en) Female urinary incontinence treatment device and method
US20080132944A1 (en) Suture re-tensioning device
CN104955419B (en) Medical sling
ES2642893T3 (en) Device for supplying a pelvic floor implant
US8206282B2 (en) Peyronie's treatment device
US9795483B2 (en) Peyronie's treatment implant
RU2694474C1 (en) Method anogenital correction in female
US20180368897A1 (en) Rib fixation device
KR101713478B1 (en) Suture
RU2552692C1 (en) Method for biceps tendon grafting
SU1409238A1 (en) Method of treatment of inguinal cryptorchism
RU2510249C1 (en) Method of treating hip dislocation in small laboratory animals
RU2017466C1 (en) Method for recovering tendon of musculus quadriceps femoris
US20090093827A1 (en) Subcutaneous waist band and methods related thereto

Legal Events

Date Code Title Description
AS Assignment

Owner name: COLOPLAST A/S, DENMARK

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:DEITCH, SARAH J., MS.;COLLEY, JANELL, MS.;KERKVLIET, JULIE, MS.;AND OTHERS;SIGNING DATES FROM 20101202 TO 20101215;REEL/FRAME:025791/0294

STCF Information on status: patent grant

Free format text: PATENTED CASE

FPAY Fee payment

Year of fee payment: 4

MAFP Maintenance fee payment

Free format text: PAYMENT OF MAINTENANCE FEE, 8TH YEAR, LARGE ENTITY (ORIGINAL EVENT CODE: M1552); ENTITY STATUS OF PATENT OWNER: LARGE ENTITY

Year of fee payment: 8